ReviewCurrent gastroenterology reports2014
Therapeutic drug monitoring in inflammatory bowel disease: current state and future perspectives.
Review in Current gastroenterology reports, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 94 citations in OpenAlex.
- Immunogenicity of an adalimumab biosimilar, FKB327, and its reference product in patients with rheumatoid arthritis.International journal of rheumatic diseases · 2020Trial
- Trial
- Tissue transcriptional programs stratify Crohn's disease by therapeutic response and clinical outcomes.Scientific reports · 2026Article
- Application of single-cell sequencing in the study of immune cell infiltration in inflammatory bowel disease and colorectal cancer.World journal of gastrointestinal oncology · 2025Review
- Performance of a New Rapid Point-of-Care Test for Infliximab Levels in Patients with Inflammatory Bowel Disease: A Comparison to ELISA.Digestive diseases and sciences · 2024Observational
- Comparison of 3 Enzyme-Linked Immunoassay Methods to Evaluate Serum Concentrations of Infliximab and Antibodies to Infliximab in 32 Patients with Moderate to Severe Inflammatory Bowel Disease.Medical science monitor : international medical journal of experimental and clinical research · 2023Article
- Treatment With Adalimumab 80 mg Every Other Week in Inflammatory Bowel Disease: Results of Treatment Intensification in Clinical Practice.Crohn's & colitis 360 · 2023Article
- A Practical Guide to Therapeutic Drug Monitoring of Biologic Medications for Inflammatory Bowel Disease.Journal of clinical medicine · 2021Review
- Therapeutic Drug Monitoring of Tumor Necrosis Factor Antagonists in Crohn Disease: A Theoretical Construct to Apply Pharmacokinetics and Guidelines to Clinical Practice.Inflammatory bowel diseases · 2021Review
- Therapeutic Drug Monitoring for Current and Investigational Inflammatory Bowel Disease Treatments.Journal of clinical gastroenterology · 2021Review
- The effect of early trough level of infliximab on subsequent disease course in patients with Crohn disease: A prospective cohort study.Medicine · 2020Observational
- Determination of lower cut-off levels of adalimumab associated with biochemical remission in Crohn's disease.JGH open : an open access journal of gastroenterology and hepatology · 2020Article
- Dried blood samples can support monitoring of infliximab concentrations in patients with inflammatory bowel disease: A clinical validation.British journal of clinical pharmacology · 2019Observational
- Clinically important neutralizing anti-drug antibodies detected with an in-house competitive ELISA.Clinical rheumatology · 2019Article
- Accuracy of the new rapid test for monitoring adalimumab levels.Therapeutic advances in gastroenterology · 2019Article
- Clinical Pharmacokinetic and Pharmacodynamic Considerations in the Treatment of Ulcerative Colitis.Clinical pharmacokinetics · 2019Review
- Routinely utilized in-house assays for infliximab, adalimumab and their anti-drug antibody levels.Immunologic research · 2018Article
- The performance of Remicade®-optimized quantification assays in the assessment of Flixabi® levels.Therapeutic advances in gastroenterology · 2018Article
- Exposure-response relationship of certolizumab pegol induction and maintenance therapy in patients with Crohn's disease.Alimentary pharmacology & therapeutics · 2018Article
- Immunogenicity of biologics in inflammatory bowel disease.Therapeutic advances in gastroenterology · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Current available anti-inflammatory drugs, in particular monoclonal antibodies directed against the cytokine tumor necrosis factor α (TNF), have greatly enhanced the treatment of inflammatory bowel diseases (IBD). Although many patients respond to ant-TNF therapy, a proportion of patients will not respond (primary non-response) or will lose response to the drug over time (secondary non-response). This loss of response can be caused by patient, TNF-inhibitor, or disease-related factors influencing the pharmacokinetics and pharmacodynamics of the drug. Therefore, monitoring pharmacological parameters (i.e. therapeutic drug monitoring) may help guide therapeutic decisions. This review emphasizes interesting and important new findings, and provides an updated overview, on the subject of therapeutic drug monitoring. While exploring the hypothesis that "one size does not fit all", we focused on the first prospective studies investigating the novel approach in IBD of 'target concentration adjusted dosing' and personalized medicine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.